137 related articles for article (PubMed ID: 36507931)
21. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
22. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Zhu J; Wu Q; Wang J; Niu T
Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
26. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES; Montesinos P; Minden MD; Lee JH; Heuser M; Naoe T; Chou WC; Laribi K; Esteve J; Altman JK; Havelange V; Watson AM; Gambacorti-Passerini C; Patkowska E; Liu S; Wu R; Philipose N; Hill JE; Gill SC; Rich ES; Tiu RV
Blood; 2022 Oct; 140(17):1845-1857. PubMed ID: 35917453
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Gaudy A; Laille E; Bailey R; Zhou S; Skikne B; Beach CL
Clin Pharmacol Ther; 2023 Oct; 114(4):845-852. PubMed ID: 37422689
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
29. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
30. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
31. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
Jen EY; Wang X; Li M; Li H; Lee SL; Ni N; Przepiorka D; Vallejo J; Leong R; Ma L; Gehrke BJ; McLamore S; Theoret MR; de Claro RA
Clin Cancer Res; 2022 Jul; 28(14):2989-2993. PubMed ID: 35325108
[TBL] [Abstract][Full Text] [Related]
33. Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Zheng F; Li Q; Yang S; Zhou Z; Zeng Q; Liu K
Hematology; 2023 Dec; 28(1):2276550. PubMed ID: 37916643
[TBL] [Abstract][Full Text] [Related]
34. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
Straube J; Lane SW; Vu T
Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
[TBL] [Abstract][Full Text] [Related]
35. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
36. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
38. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S; Itzykson R; Seegers V; Recher C; Raffoux E; Quesnel B; Delaunay J; Cluzeau T; Marfaing Koka A; Stamatoullas A; Chaury MP; Dartigeas C; Cheze S; Banos A; Morel P; Plantier I; Taksin AL; Marolleau JP; Pautas C; Thomas X; Isnard F; Beve B; Chait Y; Guerci A; Vey N; Dreyfus F; Ades L; Ifrah N; Dombret H; Fenaux P; Gardin C;
Am J Hematol; 2014 Apr; 89(4):410-6. PubMed ID: 24375487
[TBL] [Abstract][Full Text] [Related]
39. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
[TBL] [Abstract][Full Text] [Related]
40. [Multicenter Prospective Study of Different Induction Regimens of Azacytidine in Treatment of Elderly Patients with Acute Myeloid Leukemia].
Wang CZ; Chu XX; Yu HY; Yang EQ; Wang L; Deng XZ; Ran XH; Wang LQ; Zhao CT; Liu XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1005-1013. PubMed ID: 37551469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
